Letrozol Accord (Letrozole)

Letrozole works by selectively and non‑steroidally blocking the aromatase enzyme, which converts adrenal and ovarian androgens into estrogen. By inhibiting this conversion, circulating estrogen concentrations fall, depriving estrogen‑dependent cancer cells of a key growth signal.

The specific dose of Letrozol Accord is determined by the prescribing physician based on the patient’s clinical condition, treatment setting and individual factors. Healthcare providers follow established guidelines and adjust the regimen as needed for safety and efficacy.

Letrozol Accord is classified as pregnancy category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended during breastfeeding, as it may pass into milk and affect the infant.

To order Letrozol Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Accord (letrozole) is a third‑generation aromatase inhibitor with high potency and a long half‑life, offering once‑daily dosing. Compared with earlier agents such as anastrozole, letrozole generally provides slightly greater estrogen suppression, though clinical choice depends on individual patient factors and physician preference.

Letrozol Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and heat sources. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Letrozol Accord is taken orally, usually as a whole tablet swallowed with water. It is administered once daily, preferably at the same time each day, and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include severe liver injury, significant bone loss leading to fractures, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should report signs of jaundice, persistent bone pain, or any rash with swelling promptly to their physician.

Letrozol Accord should not be used by pregnant women, individuals with known hypersensitivity to letrozole or any tablet excipients, and patients with severe hepatic impairment. Caution is also advised for those with pre‑existing osteoporosis or uncontrolled cardiovascular disease.